FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979485853> ?p ?o ?g. }

• W2979485853 endingPage "1011" @default.
• W2979485853 startingPage "1011" @default.
• W2979485853 abstract "Abstract Abstract 1011 Background. CMR was introduced in London to assess myocardial iron loading in 1999 and some of these patients now have 10 years of follow-up, most with contemporary CMR determinations. The impact of long-term monitoring of myocardial iron loading in thalassemia major (TM) on the proportion of patients with increased myocardial iron (cT2* <20ms) and on patterns of mortality has not been previously described in a longitudinal cohort over this duration. Patients and Methods. All patients regularly attending two London thalassemia centres, who received their first CMR Jan 1999 - Dec 2000 were analyzed as a cohort. Patients underwent initial CMR at the Royal Brompton Hospital and received CMR follow up (FU) either there or at the Heart Hospital (UCLH). 132 patients were identified as having received a CMR in 1999–2000. A minimum 7 years CMR FU was required for inclusion in the long-term CMR analysis. 109 patients had at least 7 years of CMR follow up (range 7.0–10.6 years, median 9.2). The median age at 1st CMR was 27.9 years (range 7.7 – 49.5 years). At baseline, patients were receiving chelation with deferoxamine (DFO) monotherapy (70%), deferiprone (DFP) monotherapy (21%), or a combination of these agents (9%). At latest FU, patients were receiving DFO (32%), deferasirox (DFX) (28%), DFP (22%), or combined DFP and DFO therapy (18%). Results: Improvement in cardiac iron: In 1999–2000, 60% of TM patients had cT2* values ≤20ms and 17% had cT2* values <10ms. By contrast, at long term FU, only 23% now have cT2* ≤20ms, 7% have cT2* values <10ms (p<0.001). Changes to chelation therapy: 31% of patients stayed on the same chelator; 33% had 1 chelator switch, 26% 2 switches and 11% 3 or more switches. 18 switches in chelation therapy were due to side-effects (12 DFP, 5 DFX, 1 DFO). There were 9 breaks in chelation therapy during pregnancy in 8 different women. The proportions of patients with T2* < 20ms fell significantly for those who remained on DFO or DFP monotherapies throughout, or who changed chelation modalities on only one (p=0.002) or two (p=0.02) occasions. Patients who received had 3 or more switches did not show a improvement in this respect. The latter group was also the only subset that showed significant deterioration in myocardial iron (p<0.001). Mortality rates: the overall mortality rate for the initial cohort was 1.65 per 1000 patient years (95% CI 0.71 – 3.24); median age at death 35.6 years (range 27.3–48.4). This is a substantial improvement in the mortality index compared with the UK thalassemia registry data, of 4.3 per 1000 patient years during the period 2000–2003 (Modell et al, JCMR, 2008). The incidence rate ratio is 0.387 (95% CI 0.11–0.961), p<0.05, with patients in our cohort 61% less likely to die than those in the 2000–2003 cohort. Causes of death: there were 8 deaths during the FU period: 3 with complications of hepatitis C (all with cT2* > 20ms), 3 with sepsis (2 with cT2* <10ms and impaired ejection fraction, 1 with cT2* of 18ms), 1 with breast cancer, 1 with sudden unexplained death (cT2* > 20ms). Thus in only 2 patients could excessive cardiac iron loading be considered a causal/contributory factor. There was no significant difference in the baseline cT2* between those who died and those currently still alive (p= 0.2), meaning that death as a drop-out cause does not explain iron loading trends over FU. Chelators at death: DFO (4), DFP (2), DFX (1), combination (1). Conclusions: Over a decade we have seen an almost 3 fold fall in the proportion of patients with myocardial iron overload. Mortality has become substantially lower and cardiac iron overload is no longer the leading cause of mortality. In addition to CMR, this decade has seen the advent of two new oral iron chelators and many patients switched chelation regimen, sometimes several times, during the follow up period. Whilst the contribution of the individual components of this practice to the improved outcome cannot be concluded without randomized studies, it is clear that this modern management of TM is associated with reduced TM mortality. Disclosures: Off Label Use: Deferiprone is off label in the USA but licensed in Europe. Shah:Novartis: Honoraria, Speakers Bureau; Apotex/ Swedish Orphan: Honoraria. Pennell:Siemens: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Apotex: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Cardiovascular Imaging Solutions: Director of CVIS, Equity Ownership. Porter:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau." @default.
• W2979485853 created "2019-10-18" @default.
• W2979485853 creator A5003474421 @default.
• W2979485853 creator A5015705263 @default.
• W2979485853 creator A5029623269 @default.
• W2979485853 creator A5048988967 @default.
• W2979485853 creator A5049244658 @default.
• W2979485853 creator A5054773163 @default.
• W2979485853 creator A5087913162 @default.
• W2979485853 creator A5091168003 @default.
• W2979485853 date "2010-11-19" @default.
• W2979485853 modified "2023-10-03" @default.
• W2979485853 title "A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality" @default.
• W2979485853 doi "https://doi.org/10.1182/blood.v116.21.1011.1011" @default.
• W2979485853 hasPublicationYear "2010" @default.
• W2979485853 type Work @default.
• W2979485853 sameAs 2979485853 @default.
• W2979485853 citedByCount "12" @default.
• W2979485853 countsByYear W29794858532012 @default.
• W2979485853 countsByYear W29794858532013 @default.
• W2979485853 countsByYear W29794858532014 @default.
• W2979485853 countsByYear W29794858532015 @default.
• W2979485853 countsByYear W29794858532016 @default.
• W2979485853 countsByYear W29794858532018 @default.
• W2979485853 countsByYear W29794858532021 @default.
• W2979485853 countsByYear W29794858532022 @default.
• W2979485853 crossrefType "journal-article" @default.
• W2979485853 hasAuthorship W2979485853A5003474421 @default.
• W2979485853 hasAuthorship W2979485853A5015705263 @default.
• W2979485853 hasAuthorship W2979485853A5029623269 @default.
• W2979485853 hasAuthorship W2979485853A5048988967 @default.
• W2979485853 hasAuthorship W2979485853A5049244658 @default.
• W2979485853 hasAuthorship W2979485853A5054773163 @default.
• W2979485853 hasAuthorship W2979485853A5087913162 @default.
• W2979485853 hasAuthorship W2979485853A5091168003 @default.
• W2979485853 hasConcept C126322002 @default.
• W2979485853 hasConcept C126838900 @default.
• W2979485853 hasConcept C141071460 @default.
• W2979485853 hasConcept C143409427 @default.
• W2979485853 hasConcept C164705383 @default.
• W2979485853 hasConcept C187212893 @default.
• W2979485853 hasConcept C2776008845 @default.
• W2979485853 hasConcept C2776517179 @default.
• W2979485853 hasConcept C2776672577 @default.
• W2979485853 hasConcept C2777218474 @default.
• W2979485853 hasConcept C2777799968 @default.
• W2979485853 hasConcept C2781053155 @default.
• W2979485853 hasConcept C2987145844 @default.
• W2979485853 hasConcept C71924100 @default.
• W2979485853 hasConcept C72563966 @default.
• W2979485853 hasConceptScore W2979485853C126322002 @default.
• W2979485853 hasConceptScore W2979485853C126838900 @default.
• W2979485853 hasConceptScore W2979485853C141071460 @default.
• W2979485853 hasConceptScore W2979485853C143409427 @default.
• W2979485853 hasConceptScore W2979485853C164705383 @default.
• W2979485853 hasConceptScore W2979485853C187212893 @default.
• W2979485853 hasConceptScore W2979485853C2776008845 @default.
• W2979485853 hasConceptScore W2979485853C2776517179 @default.
• W2979485853 hasConceptScore W2979485853C2776672577 @default.
• W2979485853 hasConceptScore W2979485853C2777218474 @default.
• W2979485853 hasConceptScore W2979485853C2777799968 @default.
• W2979485853 hasConceptScore W2979485853C2781053155 @default.
• W2979485853 hasConceptScore W2979485853C2987145844 @default.
• W2979485853 hasConceptScore W2979485853C71924100 @default.
• W2979485853 hasConceptScore W2979485853C72563966 @default.
• W2979485853 hasIssue "21" @default.
• W2979485853 hasLocation W29794858531 @default.
• W2979485853 hasOpenAccess W2979485853 @default.
• W2979485853 hasPrimaryLocation W29794858531 @default.
• W2979485853 hasRelatedWork W2031809642 @default.
• W2979485853 hasRelatedWork W2050427403 @default.
• W2979485853 hasRelatedWork W2109853368 @default.
• W2979485853 hasRelatedWork W2156469375 @default.
• W2979485853 hasRelatedWork W2161385556 @default.
• W2979485853 hasRelatedWork W2166561415 @default.
• W2979485853 hasRelatedWork W2187575468 @default.
• W2979485853 hasRelatedWork W2397435675 @default.
• W2979485853 hasRelatedWork W2440502035 @default.
• W2979485853 hasRelatedWork W4379507837 @default.
• W2979485853 hasVolume "116" @default.
• W2979485853 isParatext "false" @default.
• W2979485853 isRetracted "false" @default.
• W2979485853 magId "2979485853" @default.
• W2979485853 workType "article" @default.